BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
USA - NASDAQ:BIOX - KYG1117K1141 - Common Stock
1.91 USD
+0.15 (+8.52%)
2 USD
+0.09 (+4.71%)
BIOX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 83 industry peers in the Chemicals industry. Both the profitability and financial health of BIOX have multiple concerns. BIOX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BIOX had negative earnings in the past year.
In the past year BIOX had a positive cash flow from operations.
In multiple years BIOX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
BIOX has a Return On Assets of -1.13%. This is in the lower half of the industry: BIOX underperforms 63.86% of its industry peers.
BIOX has a Return On Equity of -2.94%. This is in the lower half of the industry: BIOX underperforms 61.45% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.08%, BIOX is in line with its industry, outperforming 42.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROIC | 3.08% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 5.69%, BIOX is doing worse than 61.45% of the companies in the same industry.
BIOX has a better Gross Margin (39.83%) than 84.34% of its industry peers.
BIOX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
2. Health
2.1 Basic Checks
BIOX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
There is no outstanding debt for BIOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
The Debt to FCF ratio of BIOX is 9.52, which is on the high side as it means it would take BIOX, 9.52 years of fcf income to pay off all of its debts.
BIOX's Debt to FCF ratio of 9.52 is fine compared to the rest of the industry. BIOX outperforms 65.06% of its industry peers.
BIOX has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.28, BIOX is in the better half of the industry, outperforming 79.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Altman-Z | N/A |
ROIC/WACC0.35
WACC8.84%
2.3 Liquidity
BIOX has a Current Ratio of 1.02. This is a normal value and indicates that BIOX is financially healthy and should not expect problems in meeting its short term obligations.
BIOX has a Current ratio of 1.02. This is amonst the worse of the industry: BIOX underperforms 91.57% of its industry peers.
A Quick Ratio of 0.74 indicates that BIOX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.74, BIOX is doing worse than 85.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BIOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1457.63%.
Looking at the last year, BIOX shows a very negative growth in Revenue. The Revenue has decreased by -28.28% in the last year.
The Revenue has been growing by 14.09% on average over the past years. This is quite good.
EPS 1Y (TTM)-1457.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2233.33%
Revenue 1Y (TTM)-28.28%
Revenue growth 3Y0.49%
Revenue growth 5Y14.09%
Sales Q2Q%-39.76%
3.2 Future
BIOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.67% yearly.
Based on estimates for the next years, BIOX will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.
EPS Next Y68.16%
EPS Next 2Y49.09%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-6.3%
Revenue Next 2Y6.65%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BIOX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
BIOX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BIOX is cheaper than 75.90% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BIOX is valued cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.17 | ||
| EV/EBITDA | 7.51 |
4.3 Compensation for Growth
BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.09%
EPS Next 3Y39.47%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.91
+0.15 (+8.52%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners32.2%
Inst Owner Change-0.19%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap119.78M
Revenue(TTM)333.38M
Net Income(TTM)-9059700
Analysts80
Price Target5.48 (186.91%)
Short Float %1.37%
Short Ratio1.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.45%
Min EPS beat(2)-89.82%
Max EPS beat(2)86.93%
EPS beat(4)1
Avg EPS beat(4)-297.85%
Min EPS beat(4)-1076.47%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-217.21%
EPS beat(12)2
Avg EPS beat(12)-43.03%
EPS beat(16)3
Avg EPS beat(16)-46.14%
Revenue beat(2)0
Avg Revenue beat(2)-13.11%
Min Revenue beat(2)-19.15%
Max Revenue beat(2)-7.07%
Revenue beat(4)0
Avg Revenue beat(4)-13.33%
Min Revenue beat(4)-19.15%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-8.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.28%
Revenue beat(16)8
Avg Revenue beat(16)9.32%
PT rev (1m)0%
PT rev (3m)-27.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-221.95%
EPS NY rev (3m)-221.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)-5.48%
Revenue NY rev (3m)-12.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.31 | ||
| P/FCF | 4.17 | ||
| P/OCF | 2.54 | ||
| P/B | 0.39 | ||
| P/tB | 8.28 | ||
| EV/EBITDA | 7.51 |
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)0.46
FCFY23.97%
OCF(TTM)0.75
OCFY39.36%
SpS6.11
BVpS4.92
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROCE | 4.68% | ||
| ROIC | 3.08% | ||
| ROICexc | 3.36% | ||
| ROICexgc | 10.83% | ||
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% | ||
| FCFM | 7.49% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 77.16% | ||
| Cap/Sales | 4.81% | ||
| Interest Coverage | 0.88 | ||
| Cash Conversion | 103.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-Score4
WACC8.84%
ROIC/WACC0.35
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1457.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2233.33%
EPS Next Y68.16%
EPS Next 2Y49.09%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-28.28%
Revenue growth 3Y0.49%
Revenue growth 5Y14.09%
Sales Q2Q%-39.76%
Revenue Next Year-6.3%
Revenue Next 2Y6.65%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-42.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y304.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y395.75%
OCF growth 3YN/A
OCF growth 5YN/A